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Historical approaches to modeling psychiatric 
disorders
Psychiatric  disorders  constitute  a  diverse  set  of  con­
ditions,  variously  impinging  on  all  domains  of  mental 
function  and  affecting  the  most  fundamental  human 
attributes:  language,  thought,  perception,  mood  and 
sense of self. Collectively, they cause a substantial public 
health  burden,  greater  than  cancers  or  cardiovascular 
disease [1]. The proportional burden is actually increasing 
as  we  learn  more  about  the  molecular  bases  of  other 
common  diseases  and  how  to  treat  them,  through  the 
application  of  molecular  genetics.  Until  recently,  these 
approaches have been difficult in psychiatry as we have 
had  few  entry  points  to  the  underlying  molecular 
mechanisms. This is now changing as psychiatric genetics 
reveals more and more specific mutations predisposing 
to psychiatric disease. These discoveries, along with revo­
lu  tionary advances in neurogenetic techniques, provide 
the means to elucidate pathogenic mechanisms through 
modeling such mutations in animals and defining their 
effects at the neurobiological level.
In the absence of such information on specific genetic 
causes,  previous  modeling  approaches  for  psychiatric 
disorders have been based either on surface similarities 
between  behavioral  assays  in  rodents  and  domains  of 
psychopathology in humans or on dissecting the psycho­
pharmacological  mechanisms  of  known  drugs  [2,3]. 
These  have  both  centered  on  the  goal  of  generating 
relevant behavioral assays that can provide platforms for 
drug screening.
The behavioral approach first defines behavioral assays 
in  animals  that  are  thought  to  mimic  symptoms  in 
particular  psychological  domains  [4,5].  Thus,  ‘learned 
helplessness’ is thought to model depressive symptoms, 
spontaneous alternation or latent inhibition are believed 
to  index  working  memory,  which  is  often  deficient  in 
schizophrenia,  and  decreased  social  interactions  in 
rodents are thought to relate to similar effects in humans 
with autism. Animals can be generated with defects in 
any of these or similar domains by a variety of manipu­
lations, including pharmacological, surgical, experiential 
and genetic. The relevance (or predictive validity) of these 
models  to  human  psychopathology  has  generally  been 
tested  by  whether  they  are  responsive  to  known 
medications,  such  as  antidepressants  or  antipsychotics 
[3].  Using  these  approaches,  it  has  been  possible  to 
generate a large number of such models, which have been 
used  to  screen  through  drug  libraries  for  novel  thera­
peutic compounds or to test prototypes of existing medi­
ca  tion. Unfortunately, these approaches have yielded few 
new drugs [6,7].
There are several drawbacks to using only the criterion 
of  response  to  known  medication.  First,  most  of  the 
models  do  not  have  causal  etiological  validity  ­  acute 
blockade  of  NMDA­type  receptors  for  glutamate  or 
ventral  hippocampal  lesion  are  not  actual  causes  of 
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between rodent and human behavior may be misleading. 
On the contrary, we should expect some of the underlying 
neurobiological defects to manifest at the behavioral level 
in species­specific ways, which may or may not appear 
related [2]. Third, defining predictive validity based on 
responsiveness  to  known  drugs  inevitably  restricts  the 
focus  to  mechanisms  affected  by  those  drugs.  This 
circularity has undoubtedly contributed to the paucity of 
new drug mechanisms being found.
A complementary approach is now becoming possible 
as  particular  mutations  causing  psychiatric  illness  are 
being  identified  at  an  ever­increasing  rate.  Mouse 
models  of  these  mutations  can  now  be  investigated 
using increasingly powerful and sophisticated tools to 
get  at  the  underlying  neurobiology  and  elucidate 
pathogenic  mechanisms,  from  the  level  of  synapses 
formed between specific cell types in specific circuits to 
the level of dynamic function of neuronal networks and 
concomitant moment­to­moment behavior. These types 
of  approaches  should  provide  the  necessary  neuro­
biological  knowledge  to  enable  the  rational  design  of 
new therapeutics.
A revolution in psychiatric genetics
The field of psychiatric genetics is undergoing a profound 
paradigm shift. For several decades, the prevailing model 
has held that psychiatric disorders arise in any individual 
due  to  the  cumulative  effects  of  a  large  number  of 
common variants [8­10]. Each of these, by themselves, 
would  have  a  very  small  effect  on  risk,  but  when  the 
collective  burden  of  such  alleles  passes  a  putative 
threshold, the system would be pushed into a pathogenic 
state. Though this model has little empirical support, it 
provided  the  theoretical  foundation  for  genome­wide 
association  studies  (GWAS)  [11],  which  aim  to  detect 
such variants by comparing allele frequencies for millions 
of such variants between cases and controls [12­15]. For 
psychiatric disorders, these studies, now carried out on 
tens of thousands of people, have yielded a number of 
replicated common variants reaching the threshold for 
genome­wide  significance  [16­26].  These  include  eight 
loci for schizophrenia [26,27], two for bipolar disorder 
[25]  and  one  for  schizophrenia  and  bipolar  disorder 
together [25]; three potential loci arising from individual 
GWAS for autism [22­24] have not yet been replicated on 
the same scale. These findings point to loci that may be 
involved in disease risk at a population level but do not 
identify or speak to the likely allelic frequency of causal 
variants [28]. Each of the associated variants has a tiny 
statistical  effect  on  risk  at  the  population  level  and, 
collectively, the significant single nucleotide polymorph­
isms statistically account for only a few percent of the 
overall heritability of the disorder [18,25,26].
The alternative model is that psychiatric disorders arise 
due to mutations in any of a very large number of genes 
[11,29­33].  Under  this  model,  psychiatric  diagnostic 
categories are actually umbrella terms for large numbers 
of  distinct  genetic  disorders  that  happen  to  result  in 
similar spectra of symptoms. This is the sort of genetic 
heterogeneity that underlies categories such as congenital 
deafness, epilepsy, mental retardation, retinitis pigmen­
tosa, many cancers and other conditions [34,35].
It  has,  of  course,  been  known  for  some  time  that 
psychiatric  illness  could  arise  due  to  single  mutations. 
Well­known examples include fragile X syndrome [36], 
Rett syndrome [37] and mutations in the neuroligin genes 
NLGN3 and NLGN4 [38], all of which are associated with 
autistic spectrum disorder, and velocardiofacial syndrome 
(22q11.2 deletion syndrome) [39] and the Scottish DISC1 
translocation  [40],  which  are  associated  with  schizo­
phrenia and other psychiatric diagnoses. The number of 
such  identified  mutations  is  now  steadily  and  rapidly 
increasing,  thanks  to  the  application  of  new  genomic 
microarray [41,42] and sequencing technologies [43,44], 
to the point where they collectively explain an appreciable 
fraction of psychiatric diagnoses.
Copy  number  variants  (deletions  or  duplication  of 
chromosomal segments, often affecting multiple genes) 
have been most readily identified and make up an impor­
tant class of causal mutations in schizophrenia [42,45­51], 
autism [41,52­54], attention deficit­hyper  activity disorder 
[55­58],  Tourette  syndrome  [59],  developmental  delay 
and mental retardation [60,61], epilepsy [62] and cortical 
malformations  [63].  Whole­exome  and  whole­genome 
sequencing  approaches  are  now  also  identifying  large 
numbers of point mutations individually responsible for 
psychiatric conditions [64­71].
A number of important principles have emerged from 
these studies. First, there is considerable overlap in the 
genetic etiology of what had previously been considered 
distinct disorders. Individual mutations that predispose 
to one class of psychiatric illness, such as schizophrenia, 
are also associated with other disorders, such as bipolar 
disorder, autism, mental retardation, epilepsy, attention 
deficit  hyperactivity  disorder  and  Tourette’s  syndrome 
(for example, [31,72­77]), in agreement with recent epi­
demio  logical  data  indicating  shared  risk  [78­83]. 
Traditional  diagnostic  categories,  although  still  very 
useful  in  organizing  daily  practice  in  psychiatry,  may 
therefore represent not natural kinds in terms of etiology, 
but more or less distinct phenotypic endpoints that may 
arise from common origins.
Second,  the  mutations  so  far  discovered  are  charac­
terized  by  incomplete  penetrance  and  variable  expres­
sivity [31,77,84]. As with the DISC1 translocation, such 
mutations may result in a range of phenotypes and many 
carriers may be unaffected by any psychiatric condition 
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type  is  being  assessed  ­  it  will  be  lowest  for  specific 
diagnoses,  higher  for  psychiatric  illness  generally  and 
higher  still  for  neurobiological  endophenotypes,  which 
may be apparent even in clinically unaffected carriers.
Third, many of the identified genes are involved in neural 
development [42,77,86]. While certainly not exclu  sive, this 
is  probably  the  largest  category  of  suscep  tibility  genes. 
Genes involved in activity­dependent synaptic plasticity, 
such as FMR1, are also highly represented. With increasing 
numbers  of  genes  being  identified  all  the  time,  it  is 
becoming  possible  to  assign  many  of  them  to  specific 
biochemical  pathways  or  cellular  processes,  such  as 
synapse formation and plasticity (for example, [64,66,87­89]).
Fourth,  allelic  specificity  and  dosage  are  extremely 
important.  Different  mutations  in  the  same  gene  may 
result in very different phenotypic outcomes. As a classic 
example,  Duchenne  muscular  dystrophy  and  Becker’s 
muscular  dystrophy  are  caused  by  different  types  of 
mutations in the dystrophin gene: their clinical severity, 
manifestation,  and  age  of  onset  are  also  different  [90]. 
Similar effects are seen for genes implicated in neuro­
logical  and  psychiatric  disorders  [32,35],  as  described 
later. In addition, some alleles may cause severe neuro­
logical  disorders  when  homozygous  but  manifest  as 
psychiatric illness in heterozygous form [32,35,91].
Fifth, while these findings highlight the importance of 
rare  single  mutations,  they  do  not  necessarily  imply  a 
simple  mode  of  inheritance.  Many  of  the  mutations 
found so far show a dominant effect, but recessive muta­
tions are likely to also contribute a sizeable fraction of 
cases [71,92]. In addition, there is likely to be an impor­
tant  role  for  modifying  mutations  in  the  genetic 
background that can alter the phenotypic expression of 
the ‘primary’ mutation. This is the norm, even for the 
most  classically  ‘Mendelian’  disorders  [35,77,93].  One 
should thus expect a distribution of genetic mechanisms 
across cases ­ some will be caused by highly penetrant 
mutations, others by mutations with more variable out­
come, which are modified to some extent by the genetic 
background, and yet others will involve the inheritance of 
two or more distinct mutations [35,77,94­96].
Sixth, the eventual phenotype will also be modified by 
non­genetic factors, including (i) intrinsic developmental 
variation, where the phenotypic outcome varies due to 
inherent  noise  in  the  molecular  processes  mediating 
neurodevelopment  [97],  and  (ii)  environmental  risk 
factors, which have been implicated by epidemiological 
studies.  For  schizophrenia,  for  example,  these  include 
maternal  infection,  urbanicity,  migration  and  cannabis 
use [98]. The impact of such factors in individuals may be 
highly uneven and dependent on genotype.
Despite these complexities, the major finding is clear: 
mutations  with  large  effect  on  risk  of  psychiatric 
disorders exist and we now have the means to identify 
them. If we think of this as a genetic screen for mutations 
causing a specific phenotype, with demonstrated satura­
tion mutagenesis of the human population [32], then the 
most effective approach to follow up these discoveries is 
clear: find the mutations of largest effect and use these as 
entry points to elucidate the underlying biology.
Bone fide models of genetic etiology
Advances in genetic engineering allow us to recapitulate 
human mutations in mice, and increasingly in rat. It is 
possible to generate animals with full gene knock­outs, 
conditional removal of the gene with spatial and temporal 
control, knock­in of exact human alleles, and to precisely 
engineer genomic deletions or duplications into syntenic 
regions of mouse chromosomes, thereby yielding animal 
models with direct construct validity; that is, where the 
manipulation  is  an  actual  cause  of  the  condition  in 
humans  [99,100].  An  emerging  principle  is  the  impor­
tance of allelic specificity for phenotypic outcome. For 
example,  mouse  mutants  of  Nlgn3  and  Shank3  that 
recapitu  late  human  alleles  found  in  autism  patients 
demon  strate selective effects that differ from null alleles 
[101­103]. Mice modeling human deletions or duplica­
tions can also be generated [104­106], and phenotypically 
compared with mutations of single genes in the affected 
regions  in  order  to  track  down  the  specific  culprits 
[107,108].
The number of models generated to date that directly 
recapitulate  or  mimic  the  effects  of  human  alleles  is 
small, but they have already begun to reveal details of the 
mechanisms of pathogenesis in specific mutants and to 
highlight convergent pathways, as well as some important 
general principles. For example, mutations in Nlgn, Nrxn 
(encoding  a  neurexin),  Shank3  (encoding  an  adaptor 
protein that interacts with the cytoplasmic tails of Nlgn 
proteins) and Cntnap2 (which also encodes a member of 
the neurexin protein family) all affect synapse formation, 
altering the biochemical composition of synapses and the 
balance  between  excitation  and  inhibition  between 
specific cell types in developing neuronal networks, with 
a range of concomitant behavioral deficits [101­103,109­
112]. Local and long­range circuitry can also be altered 
by defects in cell migration and axon projection, which 
have been observed in DISC1 mutants or transgenic lines 
(for  example,  [113,114]),  paralleling  observations  in 
humans with DISC1 mutations [115]. Alterations in long­
range functional connectivity have also been observed ­ 
for  example,  between  cortex  and  striatum  in  Shank3 
mutant mice [111], between cortex and hippocampus in 
Df(16)A+/-  mice,  which  recapitulate  22q11.2  deletion 
[105], and in cortical synchrony in Cntnap2 mutant mice 
[112]. These kinds of observations help generate specific 
hypo  theses  regarding  the  cellular  origins  of 
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the  increasingly  sophisticated  neurogenetic  tools  avail­
able (for example, [116­118]).
Studies in some animal models, such as mice mutant in 
Fmr1 or MeCP2 (the gene for methyl CpG binding protein 
2,  mutated  in  Rett  syndrome),  have  even  suggested 
possible new therapies based on detailed understanding 
of the biochemical pathology [119­121]. Despite all these 
advances,  however,  the  complete  path  ways  of  patho­
genesis  for  any  single  case  remain  obscure.  Even  for 
Fmr1,  where  the  effects  of  mutation  of  this  gene  on 
synaptic plasticity are well described at the biochemi  cal 
and cellular levels, the ultimate impact of these changes 
on the functions of specific neural circuits and how these 
explain the observed behaviors or psycho  pathology are 
only beginning to be unraveled [122].
To fully elucidate the pathogenic mechanisms for any 
specific mutation will require the integration of analyses 
across multiple levels, from protein function to systems 
neuroscience. What are the biochemical functions of the 
mutated protein? What are the cellular effects in various 
brain  regions?  How  do  these  affect  the  function  of 
various neural circuits? How do changes in neural activity 
play  out  over  subsequent  activity­dependent  develop­
ment? What are the cascading or reactive consequences 
as the brain develops with these initial alterations? What 
are the concomitant effects on physiology and behavior? 
Which circuit defects are responsible for which behavioral 
phenotypes?  Which  are  the  ones  most  relevant  to  the 
symptoms  of  the  human  disease?  Which  are  the  ones 
most  amenable  to  intervention?  These  are  formidable 
challenges even in light of the spectacular advances in 
modern neuroscience.
Rather  than  predefining  which  areas  or  mechanisms 
are  important  or  how  we  expect  animal  models  of 
psychiatric disorders to behave, we can take a bottom­up 
approach and simply ask, for any of these mouse mutants 
‘what happens to their brain circuits?’ In analyzing the 
effects of any particular mutation it will be essential to 
consider the full cellular complexity of the circuitry and 
to use all the tools of modern molecular neuroscience to 
dissect the causal chains from primary genetic lesion to 
ultimate phenotype(s).
A cell type-based approach is key to link 
genes and circuits in discovering pathogenic 
mechanisms
Is there a generally useful strategy to tackle the problem 
of circuit pathogenesis in rodent models? If genes are the 
entry  points  to  the  cause  and  genetic  architecture  of 
psychiatric  disorder,  then  we  suggest  that  specific  cell 
types may be the next set of entry points in neurobiology 
studies  that  may  coherently  link  different  levels  of 
analysis, integrate different approaches and technologies, 
and  yield  useful  answers  in  understanding  pathogenic 
mechanisms. This is based on the following three first 
principles: individual cell types are the basic components 
of  neural  circuit  organization,  the  building  blocks  of 
circuit assembly, and the basic units of gene expression 
and  regulation  in  the  brain  (Figure  1).  Therefore,  a 
research  program  centered  around  cell  type­based 
approaches is likely to be most productive in discovering 
the  biological  processes  that  build  and  operate  neural 
circuits, and in revealing how these processes are altered 
by mutations and environmental insults.
The  focus  on  cell  types  embraces  the  importance  of 
different  types  of  synapse.  For  example,  mutations  in 
Nlgn  genes  differentially  affect  the  activity­dependent 
stabilization of excitatory (Nlgn1) or inhibitory (Nlgn2) 
synapses,  selectively  altering  levels  of  different  neuro­
trans  mitter  receptors  [123­125].  The  effect  of  Nlgn2 
muta  tion  is  specific  for  inhibitory  synapses  from  fast­
spiking (parvalbumin­positive) but not from somatostatin­
positive  interneurons  [126].  Such  effects  can  also  be 
region­specific:  Nlgn3  knock­in  mice  show  increased 
synaptic inhibition in the cortex, but increased excitatory 
synaptic  transmission  in  the  hippocampus  [102]. 
Mutations in other genes, such as Fmr1 [122] and ErbB4 
or Nrg1 [127], show similarly cell type­ and synapse type­
specific effects. Understanding the particular profile of 
effects  across  multiple  cell  types  in  each  mutant  thus 
requires  engagement  with  the  cellular  complexity  of 
these circuits. This profile will also importantly include 
compensatory changes that may be secondarily induced 
and that could play important roles in pathogenesis (for 
example, [128­131]).
However,  cell  type­based  analysis  of  neural  circuits, 
although  more  routinely  practiced  in  invertebrate 
systems, is highly challenging in the mammalian brain 
circuits, which consist of highly diverse and intermingled 
cell types that, until recently, could not be readily identi­
fied and experimentally accessed.
Fortunately,  our  ability  to  carry  out  such  cell  type­
based analyses is rapidly increasing, as new neurogenetic 
tools are developed. Gene expression profiles that define 
many cell types have been elucidated, enabling researchers 
to isolate specific genetic elements that can be used to 
drive  cell  type­specific  expression  of  a  variety  of 
transgenic constructs with different uses. These include 
tracing  axonal  projections  and  synaptic  connec  tions, 
monitoring  electrical  activity,  and  non­invasively 
activating  or  shutting  off  neurons  in  behaving  animals 
with optical methods or chemical ligands [117,132,133]. 
Combined with advances in multi­photon imaging, auto­
mated microscopy and computational resources to deal 
with very large datasets, these tools confer unprecedented 
power to dissect the structure and function of neuronal 
circuits [134,135].
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ized approach in the mouse to drive such constructs in 
specific  cell  types  [136].  This  binary  gene  expression 
system  is  an  effective  strategy  that  confers  cell  type 
specificity as well as combinatorial power. A Cre driver 
mouse line provides a ‘genetic switch’ in a cell type that, 
through  site­specific  recombination  between  loxP 
recognition sites, can turn on or off the various molecular 
probes  that  allow  these  cells  to  be  analyzed  by  all  the 
above modern techniques in their native circuit in vivo. 
An increasing number of Cre drivers thus will allow more 
systematic and integrated analysis of different cell types 
in the relevant circuits (for example, [137,138]). Further­
more,  certain  Cre  drivers  allow  tracking  the  develop­
mental history of cell types, thereby enabling a compre­
hensive analysis of these cell types, from their specifica­
tion,  migration  and  synapse  development  to  their 
integra  tion and function in the circuits. This approach 
will  be  particularly  powerful  in  revealing  how  the 
developmental  trajectories  of  cells  and  circuits  are 
altered, what are the primary cell autonomous changes 
due to ‘direct hit’ of the mutant gene, and what are the 
secondary,  possibly  maladaptive  changes  that  lead  to 
aberrant circuit­level operations. Genetic tracking of the 
development of distinct cell types thus will begin to link 
studies  of  circuit  assembly  and  function  and  their 
alterations in disease models. This can be achieved simply 
by bringing the Cre driver allele and relevant reporter 
alleles into an etiology model through breeding.
Analysis  of  multiple  circuits  brain­wide  in  a  disease 
model will allow a more unbiased ‘screen’ for deficits, less 
restricted by prior knowledge and assumptions of disease 
pathology. This will allow definition of the overall profile 
of  deficits  across  multiple  systems  in  each  individual 
mutant,  which  may  be  quite  unique.  Comparison  of 
multiple disease models promises to identify shared or 
distinct  circuit  deficits  in  these  models,  which  may 
underlie their shared or distinct behavioral phenotypes. 
To achieve this, it will be increasingly useful to establish 
high­throughput  methods  to  effectively  screen  for 
alterations  in  cell  numbers,  connectivity,  and  function 
with cell type resolution [134].
The convergence of phenotype across multiple animal 
models may arise at the biochemical or cellular level in 
some cases (such as pathways involved in synapse forma­
tion [87,88] or in cAMP signaling [139]), but only at the 
level of the emergent functions of large­scale neuronal 
networks  in  others  (such  as  the  responsiveness  of  the 
dopaminergic system [129,140] or GABAergic signaling 
and neuronal synchrony in the prefrontal cortex [131]). A 
central challenge in this framework is thus to link the 
cellular level analysis of phenotypic effects on microcircuit 
Figure 1. A framework to elucidate pathogenic mechanisms from mutations to mental illness. The effects of mutations in different genes can 
be analyzed across development on diverse cell types, local circuit organization and emergent properties, functional connectivity on a macro scale 
and correlated behavior in animals or psychopathology in humans.
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function on a larger scale. It is these emergent functions 
that  will  best  explain  behavior  or  psychopathology. 
Rather than merely demonstrating that a mouse mutant 
shows some patterns of behavior reminiscent of human 
symptomatology, it will be essential to analyze physio­
logical  measures  of  circuit  dynamics  that  explain 
behavior on a moment­to­moment basis in the relevant 
social and cognitive context.
Large-scale analysis of circuits that subserve 
behavior
The  neuroscience  of  animal  and  human  behavior  has 
witnessed a productive paradigm shift in the past decade 
where  the  trend  of  assigning  complex  traits  to  single 
genes  has  given  way  to  the  realization  that  dynamic 
coordination between micro and macro circuits is key to 
understanding the neuronal basis of behavior [141]. In 
other words, the emphasis has shifted from associating a 
behavior to a single gene or its protein product simply 
because mutation of that gene disrupts that behavior to 
understanding how functional variability at the gene or 
protein  level  influences  the  dynamic  coordination  of 
neurons in systems that support a certain behavior.
In the context of schizophrenia, the approach has been 
descriptive  and  mechanistically  naive  in  that,  for  the 
most part, it has focused on associating a common allelic 
variation, which in some cases has not even been asso­
ciated with a functional alteration, to complex behavioral 
disruptions whose physiology is still not fully understood. 
It is now increasingly being appreciated that a mecha­
nistic  understanding  of  the  pathophysiology  of  schizo­
phrenia is contingent upon (i) a better understanding of 
the  dynamic  coordination  of  neuronal  processes  that 
serve the behaviors that are disturbed in at least some 
cases  of  schizophrenia  and  (ii)  understanding  the 
functional role of implicated genes in micro and macro 
neuronal  circuits  that  subserve  this  physiology.  Recent 
studies, highlighted below, are beginning to make con­
siderable advances in these two approaches.
Electrophysiological recordings using electroencepha­
lo  graphy (EEG) have for decades reported behaviorally 
relevant  oscillatory  activity  throughout  the  cerebral 
cortex [142]. Until recently, however, these data did not 
receive much attention in the context of psychiatric dis­
orders, mostly because these measures had poor spatial 
and temporal resolution and were therefore considered 
functionally  vague.  The  advent  of  magnetoencephalo­
graphy  (MEG)  and  development  of  better  EEG  instru­
men  tation  combined  with  invasive  electrophysiological 
recordings  in  laboratory  animals  has  now  provided 
strong  evidence  that  these  measures  are  biologically 
meaningful correlates of behavior [143]. This has been in 
part  because  of  a  series  of  elegant  studies  in  animals 
establishing a relationship between single neuron activity 
and  local  field  potential  oscillations  in  behaviorally 
relevant contexts [144,145].
Animal  studies  have  further  demonstrated  that 
synchronized neuronal oscillations at various frequencies 
are  a  measure  of  coordinated  neuronal  activity  that 
supports behavior. EEG and MEG studies in humans have 
subsequently  established  a  close  relationship  between 
oscillations  at  various  frequencies  and  behavioral 
performance,  including  working  memory  and  selective 
attention [146]. This has been followed by several studies 
reporting  changes  in  neuronal  oscillations  associated 
with  cognitive  deficits  as  well  as  some  symptoms  of 
schizophrenia  [147­150].  EEG  and  MEG  are  thus 
promising  translational  methods  that  assess  oscillatory 
activity with similar temporal and spatial resolution to 
more  invasive  methods  that  can  be  used  in  behaving 
animals, as described later.
Thus, experimental procedures such as pharmaco  logi­
cal and genetic manipulations can be applied in conjunc­
tion with single unit recording and local field potentials 
to understand the molecular and cellular processes that 
could  contribute  to  abnormal  oscillatory  activities 
[151,152]. The emergent properties of neuronal networks 
depend  crucially  on  the  cellular  architecture  of  the 
micro  circuits involved and on the interactions between 
definable cell types. For example, the connectivity between 
parvalbumin­positive interneurons and pyramidal neurons 
is essential to drive oscillations in the gamma frequency, 
for  phase­locking  between  rhythms  at  differ  ent  fre­
quencies and for long­range temporal coherence between 
brain  areas,  which  subserves  cognitive  and  perceptual 
functions [116,151,153­157]. Other interneuron subtypes 
have dissociable functions on neural systems [158­161].
The  proliferation  of  cell  type­specific  genetic  drivers 
and development of optogenetic approaches also enable 
follow­up experiments to directly test hypotheses arising 
from studies of mutant phenotypes by manipulating the 
activity of the implicated cell types in highly specific ways 
[117]. Such approaches should allow the field to move 
beyond  correlations  between  various  anatomical  and 
physio  logical  disturbances  in  mutant  animals  to  direct 
tests  of  how  the  precise  connectivity  patterns  and 
strengths  between  different  cell  types  affect  the  infor­
mation­processing parameters of microcircuits and larger 
neuronal  networks  and  impact  on  specific  behaviors 
[116,118,154,162].
While mice are likely to continue to lead the way in the 
discovery of the effects of specific mutations on nervous 
system development and function, we can also expect the 
increasing use of genetically manipulated rat and primate 
models  to  further  dissect  pathophysiological  mecha­
nisms. Zinc­finger nucleases can be used to specifically 
modify  the  genome  in  effectively  any  type  of  cell, 
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generating  genetically  modified  organisms  [163].  This 
approach  has  been  used  to  generate  gene  knockouts 
[164]  and  also  to  knock  in  specific  alleles  in  the  rat 
[165,166],  opening  up  the  possibility  of  recapitulating 
human  alleles  in  this  species  and  others  in  the  future. 
Brain cells can also be genetically modified in a cell type­
specific manner by viral transfection [132,167], making 
them accessible to acute gene manipulations and also to 
optogenetic techniques in any species, including rats and 
non­human  primates  [168,169].  These  species,  which 
have a much richer tradition of systems neuroscience and 
greater cognitive sophistication than the mouse, will no 
doubt be essential in further elucidating general princi­
ples  and  mechanisms  of  pathophysiology  and  relating 
them to humans.
Translation to humans
Because  diagnostic  classification  of  mental  illnesses  in 
clinical  psychiatry  at  present  is  merely  based  on 
phenomenology and not disease etiology, it is important 
to  consider  translation  between  humans  and  rodent 
models not via clinical diagnosis but specific biological 
traits. These traits would include behavioral constructs 
and  physiological  characteristics,  and  are  crucial  in 
understanding  disease  mechanisms  in  rodent  models. 
Even more importantly, such characteristics can be used 
as indicators of drug screening in rodents and markers in 
clinical trials with humans.
A major confound in analyzing neurobiological inter­
mediate phenotypes in psychiatric patients has been the 
extreme  underlying  (and  previously  cryptic)  genetic 
hetero  geneity.  As  the  genetic  factors  involved  in 
psychiatric  illness  are  determined  in  more  and  more 
patients, it should be possible to make much more direct 
and  powerful  comparisons  of  underlying  phenotypic 
traits between genetically defined subsets of humans and 
mice carrying the same mutation. This genetic stratifi­
cation of patients may also prove invaluable in the design 
of clinical trials aimed at primary causes. On the other 
hand, the analysis of phenotypes correlated with clinical 
states  will  need  to  look  for  convergence  across  mouse 
mutants or human patients with diverse genetic causes.
Many  efforts  have  been  made  to  try  to  identify 
equivalent characteristics between humans and rodents. 
For example, at the behavioral level, the Cognitive Neuro­
science  Treatment  Research  to  Improve  Cognition  in 
Schizophrenia (CNTRICS) aims to develop and imple­
ment animal model paradigms that can tap the cognitive 
and  emotional­processing  constructs  translatable  to 
humans [170]. Although only limited numbers of para­
digms are widely accepted to be translational, collabora­
tion among human neuropsychologists and animal neuro­
behavioral scientists may identify several paradigms to be 
utilized for translation. Starting these studies with animal 
models  with  direct  etiological  validity  should  tell  us 
which behavioral constructs are really most relevant to 
human  psychopathology,  even  if  the  effects  manifest 
differently on the surface.
Given  well­founded  concerns  over  the  species­
specificity  of  behavioral  measures,  it  seems  likely  that 
neuro  physiological  measures  may  prove  to  be  more 
translatable between animals and humans. This may be 
especially true of measures of functional connectivity or 
coherence  between  brain  areas,  as  these  may  most 
powerfully  index  differences  in  network  function  that 
affect psychopathology. These can be assayed with EEG 
and MEG, as described above, but also with functional 
connectivity studies using functional magnetic resonance 
imaging  to  examine  correlations  between  activities  of 
remote but connected regions [171­174]. Although these 
measures  are  simply  about  observed  correlations,  they 
provide clinically relevant dynamic information that can 
be  invaluable  for  animal  studies,  which  can  in  turn 
provide more detailed mechanistic information about the 
neuronal basis of the reported aberrant connectivity. For 
example, the reduced synchrony between hippocampal 
and prefrontal regions in the 22q11.2 deletion Df(16)A+/- 
mice [105] parallels observations in humans with schizo­
phrenia [171], generating testable hypotheses about the 
origins of this defect [157]. Alterations in cortico­striatal 
or intracortical coherence in Shank3 [111], Fmr1 [122] 
and Cntnap2 mutant mice [112] similarly provide entry 
points to define the pathophysiology of these disorders at 
a level that can be directly assessed in humans, especially 
those with mutations in the same genes.
Definition  of  the  mouse  correlates  of  human  patho­
physiology and psychopathology will also allow a reverse 
translational approach to identify new candidate suscep­
tibility  genes.  Prospective  phenotyping  of  mice  with 
muta  tions  in  neurodevelopmental  genes  may  reveal 
pheno  types paralleling established models (for example, 
NogoA [175], Dlg4 [176], Sema6A [177] and Slitrk5 [178]). 
This gives a higher prior probability for assigning patho­
genicity in the event that mutations in those genes are 
then found in human patients.
Strategies towards new treatments
The drugs currently used to treat disorders like schizo­
phrenia  were  discovered  serendipitously,  are  only 
partially effective for positive symptoms but not the more 
debilitating  negative  and  cognitive  symptoms,  work  in 
some patients and not others and have serious side effects 
[179]. For autism spectrum disorder, the situation is even 
more bleak ­ while there are some drugs prescribed to 
treat some symptoms there is no overall therapeutic of 
proven  value  [180].  The  main  reason  hardly  any  new 
drugs  (with  novel  mechanisms)  have  been  successfully 
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understanding  of  the  underlying  mechanisms  of  these 
disorders.
New  genetic  models  may  be  utilized  in  identifying 
novel treatment strategies in three ways: first, to identify 
novel targets through which we can find more effective 
and safer compounds for treatment within the current 
understanding of these diseases; second, to identify novel 
targets and compounds that may not be obvious from 
current paradigms; third, and probably most important, 
to identify targets and compounds for early intervention.
By  analyzing  molecular,  cellular  and  circuitry  distur­
bances in new genetic models, we may find better clues 
to  how  the  cellular  pathways  involving  the  gene  of 
interest  may  interact  with  currently  accepted  patho­
physiological  paradigms  (such  as  the  roles  of  GABA, 
NMDA  receptors  and  dopamine  receptors  in  schizo­
phrenia).  In  such  cases,  we  may  identify  better  drug 
targets,  against  which  we  can  expect  compounds  with 
better efficacy and less side effects.
However, our hope is to identify new targets and com­
pounds with new genetic models. Although investigators 
who generate new genetic models tend to test whether 
current medications (such as clozapine and haloperidol 
for  schizophrenia)  can  normalize  deficits  in  behavioral 
paradigms, it may be more advantageous for new drug 
discovery  to  identify  paradigms  that  are  relevant  to 
human  diseases  (that  is,  likely  to  correlate  not  to  one 
disease but to several), but that cannot be normalized by 
current  medications.  For  example,  a  DISC1  transgenic 
mouse model with neonatal poly(I:C) treatment (to mimic 
maternal  infection)  shows  many  types  of  behavioral 
deficit, most of which are normalized by administration 
of  clozapine  [181].  However,  the  impairment  of  social 
behaviors in this model is resistant to both clozapine and 
haloperidol treatment. Provided that these impairments 
are,  at  least  in  part,  relevant  to  negative  symptoms, 
screening of novel compounds to normalize this behavior 
in  this  model  may  lead  to  the  identification  of  new 
treatments for negative symptoms.
Early intervention is now becoming a key in treatment 
strategies in many brain disorders, such as Alzheimer’s 
disease  and  schizophrenia.  Animal  models,  especially 
those  in  which  neurodevelopmentally  important  genes 
are targeted, are very useful to dissect the pathological 
course even from the premorbid stage to the full onset. 
For some symptoms, specific common phenotypes might 
be due to secondary mechanisms by which the develop­
ing brain reacts to diverse primary insults. For example, 
altered dopaminergic signaling may arise as a result of a 
variety  of  primary  defects  and  may  represent  a  final 
common pathway to psychosis [129,130,140]. The mole­
cu  lar homeostatic mechanisms underlying these secon­
dary changes may thus represent a viable target for early 
intervention in genetically at­risk subjects. Similar events 
may  underlie  the  emergence  of  dysfunction  in  other 
circuits  across  other  disorders.  In  the  case  of  schizo­
phrenia where the intervention has to occur during early 
to late adolescence, the major obstacle to moving inter­
vention to an earlier age is concerns over the effects of 
manipulating  brain  systems  that  are  still  developing. 
These concerns are compounded by a lack of concrete 
understanding  of  the  biology  of  adolescent  brain, 
especially in the context of the physiology of affect and 
cognition.  Animal  models  will,  therefore,  be  critical  in 
advancing this aspect of the field.
A way forward
The  discovery  of  mutations  that  strongly  predispose 
individuals to psychopathology provides a crucial starting 
point  to  define  pathogenic  mechanisms  and  pathways. 
Direct animal models of genetic etiology can be analyzed 
in  a  comprehensive  and  systematic  way,  using  the  full 
arsenal  of  modern  neuroscience  to  link  effects  on 
particular cell types in defined microcircuits to emergent 
properties of larger scale brain networks in behaviorally 
relevant  contexts.  These  analyses  will  hopefully  reveal 
neurobiological phenotypes that can be translated very 
directly to humans, suggest points of possible therapeutic 
intervention  and  aid  the  rational  design  of  new  drugs 
targeted at the underlying causes of mental illness.
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